Paul Thurk

Mr. Thurk joined ARCH in 2000 as a Kauffman Fellow. In 2011, he established ARCH’s European office in Dublin, Ireland to focus on European-sourced technology and investment opportunities. Mr. Thurk was co-founder and initial CEO of Innovalight (acquired by DuPont) and also CoolEdge Lighting. He co-founded Carrick Therapeutics and Genomics Medicine Ireland (acquired by WuXi NextCODE). He has participated in the development of Kotura (acquired by Mellanox), Nitronex (acquired by MACOM), Cambrios, Semprius, Movidius (acquired by Intel), Sana Biotechnology, Luna DNA, BioPalette Japan, and others. He is co-founder and current CEO of Pretzel Therapeutics.